| scholarly article | Q13442814 |
| P50 | author | Andrew P May | Q91330224 |
| Muhammed Murtaza | Q43106000 | ||
| Tim Forshew | Q55459399 | ||
| Francesco Marass | Q57192116 | ||
| P2093 | author name string | Ian Roberts | |
| Andreas Claas | |||
| Andrew Dunham | |||
| Andrew F Slatter | |||
| Tim Eisen | |||
| Nitzan Rosenfeld | |||
| Lucy Gossage | |||
| Anne Warren | |||
| Conrad P Lichtenstein | |||
| Beverley Haynes | |||
| Susan J Shanahan | |||
| P2860 | cites work | A novel MEN1 intronic mutation associated with multiple endocrine neoplasia type 1 | Q60021415 |
| A frequent somatic mutation in CD274 3'-UTR leads to protein over-expression in gastric cancer by disrupting miR-570 binding | Q83100573 | ||
| Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB | Q24309403 | ||
| BRCA1-associated protein 1 interferes with BRCA1/BARD1 RING heterodimer activity | Q24312783 | ||
| The deubiquitinating enzyme BAP1 regulates cell growth via interaction with HCF-1. | Q24323060 | ||
| Association of C-terminal ubiquitin hydrolase BRCA1-associated protein 1 with cell cycle regulator host cell factor 1 | Q24329078 | ||
| BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization | Q24337105 | ||
| Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma | Q24337664 | ||
| Frequent mutation of BAP1 in metastasizing uveal melanomas | Q24601069 | ||
| The genetic basis of early T-cell precursor acute lymphoblastic leukaemia | Q24601515 | ||
| Mutational heterogeneity in cancer and the search for new cancer-associated genes | Q24606956 | ||
| Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands | Q24631957 | ||
| Convergent structural alterations define SWItch/Sucrose NonFermentable (SWI/SNF) chromatin remodeler as a central tumor suppressive complex in pancreatic cancer | Q24633517 | ||
| COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer | Q24644945 | ||
| A genetic screen identifies novel polycomb group genes in Drosophila | Q24678399 | ||
| Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation | Q27852038 | ||
| Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network | Q27852242 | ||
| Comprehensive molecular characterization of clear cell renal cell carcinoma | Q27852374 | ||
| Integrated molecular analysis of clear-cell renal cell carcinoma | Q27852382 | ||
| A method and server for predicting damaging missense mutations | Q27860835 | ||
| Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing | Q27860948 | ||
| Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm | Q29547194 | ||
| Highly recurrent TERT promoter mutations in human melanoma | Q29614798 | ||
| Deriving the consequences of genomic variants with the Ensembl API and SNP Effect Predictor | Q29614870 | ||
| TERT promoter mutations in familial and sporadic melanoma | Q29614920 | ||
| Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes | Q29615757 | ||
| Whole-exome sequencing of human pancreatic cancers and characterization of genomic instability caused by MLH1 haploinsufficiency and complete deficiency | Q30465158 | ||
| Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer | Q33865946 | ||
| The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma | Q34190027 | ||
| Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. | Q34278191 | ||
| BAP1 loss defines a new class of renal cell carcinoma | Q34280223 | ||
| Detecting causality in complex ecosystems | Q34300961 | ||
| A novel germline mutation in BAP1 predisposes to familial clear-cell renal cell carcinoma. | Q34413144 | ||
| Predicting the functional effect of amino acid substitutions and indels | Q34441875 | ||
| An intronic mutation in MLH1 associated with familial colon and breast cancer. | Q34565224 | ||
| A del T poly T (8) mutation in the 3' untranslated region (UTR) of the CDK2-AP1 gene is functionally significant causing decreased mRNA stability resulting in decreased CDK2-AP1 expression in human microsatellite unstable (MSI) colorectal cancer (CR | Q34661572 | ||
| Prognostic significance of morphologic parameters in renal cell carcinoma. | Q34716073 | ||
| An Intronic mutation is associated with prolactinoma in a young boy, decreased penetrance in his large family, and variable effects on MEN1 mRNA and protein | Q35072652 | ||
| Renal cyst development in mice with conditional inactivation of the von Hippel-Lindau tumor suppressor | Q36446896 | ||
| Determination of the consequences of VHL mutations on VHL transcripts in renal cell carcinoma | Q36643235 | ||
| Loss of heterozygosity and copy number abnormality in clear cell renal cell carcinoma discovered by high-density affymetrix 10K single nucleotide polymorphism mapping array | Q36730935 | ||
| Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma | Q36736210 | ||
| Mutations within the 5' region of FAS/CD95 gene in nodal diffuse large B-cell lymphoma | Q36814969 | ||
| Polybromo-1: the chromatin targeting subunit of the PBAF complex | Q37107294 | ||
| Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study | Q37161942 | ||
| Somatic deletions of the polyA tract in the 3' untranslated region of epidermal growth factor receptor are common in microsatellite instability-high endometrial and colorectal carcinomas | Q37252262 | ||
| BRCA2 deep intronic mutation causing activation of a cryptic exon: opening toward a new preventive therapeutic strategy. | Q39321225 | ||
| Identification of fifteen novel germline variants in the BRCA1 3'UTR reveals a variant in a breast cancer case that introduces a functional miR-103 target site | Q39321320 | ||
| Common PIK3CA mutants and a novel 3' UTR mutation are associated with increased sensitivity to saracatinib. | Q39354437 | ||
| VHL gene mutations and their effects on hypoxia inducible factor HIFα: identification of potential driver and passenger mutations | Q39515837 | ||
| Mutation of the CDKN2A 5' UTR creates an aberrant initiation codon and predisposes to melanoma | Q40978415 | ||
| Reflex: intramolecular barcoding of long-range PCR products for sequencing multiple pooled DNAs | Q41075118 | ||
| In vitro antisense therapeutics for a deep intronic mutation causing Neurofibromatosis type 2. | Q41830290 | ||
| Analysis of VHL Gene Alterations and their Relationship to Clinical Parameters in Sporadic Conventional Renal Cell Carcinoma | Q41919666 | ||
| Mutations of the VHL tumour suppressor gene in renal carcinoma | Q42806703 | ||
| Novel intronic germline FLCN gene mutation in a patient with multiple ipsilateral renal neoplasms | Q43280338 | ||
| HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron | Q44068443 | ||
| DHPLC-based germline mutation screening in the analysis of the VHL tumor suppressor gene: usefulness and limitations | Q44847033 | ||
| Family history of von Hippel-Lindau disease was uncommon in Chinese patients: suggesting the higher frequency of de novo mutations in VHL gene in these patients | Q44847037 | ||
| CDKN2A: the IVS2-105A/G intronic mutation found in an Italian patient affected by eight primary melanomas | Q47978797 | ||
| Functional splicing assay shows a pathogenic intronic mutation in neurofibromatosis type 1 (NF1) due to intronic sequence exonization. | Q51951370 | ||
| E2F activation of S phase promoters via association with HCF-1 and the MLL family of histone H3K4 methyltransferases. | Q52681173 | ||
| A deep intronic mutation in CDKN2A is associated with disease in a subset of melanoma pedigrees. | Q52862227 | ||
| The polymorphisms in the VHL and HIF1A genes are associated with the prognosis but not the development of renal cell carcinoma. | Q53284307 | ||
| Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma | Q57177515 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 38-51 | |
| P577 | publication date | 2013-10-29 | |
| P1433 | published in | Genes, Chromosomes and Cancer | Q5532697 |
| P1476 | title | Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma | |
| P478 | volume | 53 |
| Q41242139 | A BAP1 Mutation-specific MicroRNA Signature Predicts Clinical Outcomes in Clear Cell Renal Cell Carcinoma Patients with Wild-type BAP1. |
| Q41882621 | An integrated computational approach can classify VHL missense mutations according to risk of clear cell renal carcinoma. |
| Q87245388 | BAP1 is overexpressed in black compared with white patients with Mx-M1 clear cell renal cell carcinoma: A report from the cancer genome atlas |
| Q48368561 | BRM/SMARCA2-negative clear cell renal cell carcinoma is associated with a high percentage of BRM somatic mutations, deletions and promoter methylation. |
| Q92541901 | Biomarkers of Prognosis and Efficacy of Anti-angiogenic Therapy in Metastatic Clear Cell Renal Cancer |
| Q38810854 | Cancer associated missense mutations in BAP1 catalytic domain induce amyloidogenic aggregation: A new insight in enzymatic inactivation |
| Q36105139 | Characterization of VHL missense mutations in sporadic clear cell renal cell carcinoma: hotspots, affected binding domains, functional impact on pVHL and therapeutic relevance |
| Q37573538 | Clear Cell Renal Cell Carcinoma Subtypes Identified by BAP1 and PBRM1 Expression. |
| Q90290566 | Comprehensive Analysis of BAP1 Somatic Mutation in Clear Cell Renal Cell Carcinoma to Explore Potential Mechanisms in Silico |
| Q90281138 | Comprehensive Study of the Clinical Phenotype of Germline BAP1 Variant-Carrying Families Worldwide |
| Q28397229 | Comprehensive review of BAP1 tumor predisposition syndrome with report of two new cases |
| Q38329400 | Critical roles of non-histone protein lysine methylation in human tumorigenesis |
| Q37016755 | Decreased Expression of SETD2 Predicts Unfavorable Prognosis in Patients With Nonmetastatic Clear-Cell Renal Cell Carcinoma |
| Q35640108 | Decreased PBRM1 expression predicts unfavorable prognosis in patients with clear cell renal cell carcinoma |
| Q38843978 | Different prognostic roles of tumor suppressor gene BAP1 in cancer: A systematic review with meta-analysis |
| Q38813611 | Dynamic reprogramming of DNA methylation in SETD2-deregulated renal cell carcinoma. |
| Q35677757 | Effects of preset sequential administrations of sunitinib and everolimus on tumour differentiation in Caki-1 renal cell carcinoma |
| Q90376039 | Epigenetic modifiers: activities in renal cell carcinoma |
| Q88985337 | Epigenetics in renal cell cancer: mechanisms and clinical applications |
| Q41574276 | Epigenome Aberrations: Emerging Driving Factors of the Clear Cell Renal Cell Carcinoma |
| Q38214535 | Examining the impact of gene variants on histone lysine methylation |
| Q64250041 | Extracellular Vesicles and Carried miRNAs in the Progression of Renal Cell Carcinoma |
| Q38762066 | First-Line Treatments for Poor-Prognosis Metastatic Renal Cell Carcinoma: Experts' Prescribing Practices and Systematic Literature Review |
| Q92837965 | G Protein γ subunit 7 loss contributes to progression of clear cell renal cell carcinoma |
| Q26785930 | Genetic and Chromosomal Aberrations and Their Clinical Significance in Renal Neoplasms |
| Q33709786 | Genetic characterization of Polish ccRCC patients: somatic mutation analysis of PBRM1, BAP1 and KDMC5, genomic SNP array analysis in tumor biopsy and preliminary results of chromosome aberrations analysis in plasma cell free DNA |
| Q37085985 | Genetic mutations associated with metastatic clear cell renal cell carcinoma |
| Q40243097 | Genomic alterations as predictors of survival among patients within a combined cohort with clear cell renal cell carcinoma undergoing cytoreductive nephrectomy |
| Q96610153 | Genomic profiling in renal cell carcinoma |
| Q47972869 | Genotypic and Phenotypic Features of BAP1 Cancer Syndrome: A Report of 8 New Families and Review of Cases in the Literature. |
| Q39334267 | Heterogeneity in renal cell carcinoma |
| Q26775027 | Histone methyltransferases: novel targets for tumor and developmental defects |
| Q40028818 | Imaging-genomic pipeline for identifying gene mutations using three-dimensional intra-tumor heterogeneity features |
| Q38740496 | Inhibitors of Protein Methyltransferases and Demethylases. |
| Q55337341 | Knockdown of long non-coding RNA PVT1 induces apoptosis and cell cycle arrest in clear cell renal cell carcinoma through the epidermal growth factor receptor pathway. |
| Q28073174 | Medical treatment of renal cancer: new horizons |
| Q46856592 | Modeling Renal Cell Carcinoma in Mice: Bap1 and Pbrm1 Inactivation Drive Tumor Grade |
| Q33729097 | Molecular genetics of clear-cell renal cell carcinoma |
| Q38910995 | Molecular profiling of renal cell carcinoma: building a bridge toward clinical impact |
| Q93379768 | Mutations in renal cell carcinoma |
| Q64951424 | Mutations of the MAPK/TSC/mTOR pathway characterize periventricular glioblastoma with epithelioid SEGA-like morphology–morphological and therapeutic implications. |
| Q38294198 | New insights on chromatin modifiers and histone post-translational modifications in renal cell tumours. |
| Q92154621 | Prognostic and Predictive Value of PBRM1 in Clear Cell Renal Cell Carcinoma |
| Q85939114 | Renal cell carcinoma |
| Q36639797 | Role of several histone lysine methyltransferases in tumor development |
| Q39118911 | SETting the Stage for Cancer Development: SETD2 and the Consequences of Lost Methylation |
| Q50323362 | Serum tissue factor as a biomarker for renal clear cell carcinoma |
| Q35948243 | Snail heterogeneity in clear cell renal cell carcinoma. |
| Q53153703 | The Emerging Role of Histone Demethylases in Renal Cell Carcinoma. |
| Q51091490 | The epigenetic landscape of clear-cell renal cell carcinoma. |
| Q38419495 | The hallmarks of cancer: relevance to the pathogenesis of polycystic kidney disease |
| Q42737907 | The impact of genetic heterogeneity on biomarker development in kidney cancer assessed by multiregional sampling |
| Q38811459 | The long noncoding RNA urothelial carcinoma-associated 1 overexpression as a poor prognostic biomarker in clear cell renal cell carcinoma |
| Q28083152 | The roles of chromatin-remodelers and epigenetic modifiers in kidney cancer |
| Q47592158 | Ubiquitin carboxyl-terminal hydrolases: involvement in cancer progression and clinical implications |
| Q55450682 | VHL status regulates transforming growth factor-β signaling pathways in renal cell carcinoma. |
| Q34455226 | VHL, the story of a tumour suppressor gene |
| Q39608223 | Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell Carcinoma |
| Q35551941 | miR-106b-5p targets tumor suppressor gene SETD2 to inactive its function in clear cell renal cell carcinoma |
Search more.